Chernyshov, Pavel V., Finlay, Andrew Y. ![]() Item availability restricted. |
![]() |
PDF
- Accepted Post-Print Version
Restricted to Repository staff only until 29 January 2026 due to copyright restrictions. Download (379kB) |
Abstract
In this paper, the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life (QoL) and Patient-Oriented Outcomes presents its position statements on health-related (HR) QoL assessment in epidermolysis bullosa (EB). The EADV TF on QoL and Patient-Oriented Outcomes recommends the use of the EB-specific instrument QOLEB in patients over the age of 10 years and, in addition to the QOLEB, the use of iscorEB-p in moderate-to-severe EB; the IntoDermQoL proxy instrument with its EB-specific module should be used in children aged under 5 years. The EB-specific instrument iscorEB-p, and the dermatology-specific instrument CDLQI may measure HRQoL in children with EB aged from 5 to 10 years. Dermatology-specific and/or generic HRQoL instruments should be used to compare the impact on QoL of EB with other diseases; family QoL of patients with EB should be studied using the EB-specific EB-BoD, dermatology-specific family measures, and/or generic family QoL instruments.
Item Type: | Article |
---|---|
Status: | In Press |
Schools: | Schools > Medicine |
Publisher: | Wiley |
ISSN: | 0011-9059 |
Date of First Compliant Deposit: | 5 February 2025 |
Date of Acceptance: | 29 January 2025 |
Last Modified: | 19 Feb 2025 14:15 |
URI: | https://orca.cardiff.ac.uk/id/eprint/175950 |
Actions (repository staff only)
![]() |
Edit Item |